Clinical Trials
4
Active:1
Completed:3
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Drug: FF-3 dry powderDrug: Placebo
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- Autoimmune Technologies, LLC
- Target Recruit Count
- 79
- Registration Number
- NCT02423577
- Locations
- 🇬🇧
Quintiles Drug Research Unit, London, United Kingdom
Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: Placebo for Flufirvitide-3
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Autoimmune Technologies, LLC
- Target Recruit Count
- 68
- Registration Number
- NCT01990846
- Locations
- 🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Drug: Flufirvitide-3 0.05 mg single doseOther: PlaceboDrug: Flufirvitide-3, 0.1 mg single doseDrug: Flufirvitide-3, 0.2 mg single doseDrug: Flufirvitide-3, 0.4 mg single dose
- First Posted Date
- 2011-03-14
- Last Posted Date
- 2012-01-16
- Lead Sponsor
- Autoimmune Technologies, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT01313962
- Locations
- 🇺🇸
Quintiles Phase One Services, Overland Park, Kansas, United States
News
No news found